Leverages network of more than 500 local medical institutions
Clinical and regulatory procedures underway in China; aims to expand export contracts to 50 countries by year-end

CGBIO is stepping up its efforts to enter the Taiwanese market with Facetem, its calcium hydroxyapatite (CaHA) filler product.


CGBIO said on October 13 that Facetem received medical device approval from Taiwan's Food and Drug Administration (TFDA) on May 6. The company plans to supply the product and provide training for medical professionals with its local partner, and aims to achieve cumulative supply sales of at least KRW 5 billion in Taiwan over the next three years.


CG Bio's filler product Facetem. CG Bio

CG Bio's filler product Facetem. CG Bio

View original image

Facetem is sold in South Korea under the brand name Diclasi CaHA. With this approval, it can now be sold in Taiwan for use in deep dermal and subcutaneous soft tissue augmentation.


CGBIO's Taiwan business is based on a regional licensing-out agreement it signed with HTDK Holding in 2024. HTDK's Taiwanese distribution partner, Index International, will handle local regulatory approval, distribution and sales. Index International has a cooperation network spanning more than 500 medical institutions in Taiwan. The two companies plan to use this network to expand product supply and run training and academic programs for medical professionals.


Facetem incorporates CGBIO's patented LPF technology, which creates a lattice-like porous structure inside CaHA particles. The technology was designed with the particles' structure and degradation characteristics in mind.


CGBIO currently exports Facetem to 32 countries worldwide. It aims to expand the number of countries with export contracts to more than 50 by the end of this year. In China, it is working with HTDK on clinical and regulatory approval procedures as it pursues expansion into the broader Chinese-speaking market.



CGBIO CEO Yoo Hyun-seung said, "In Taiwan, we plan to expand supply by leveraging our network of local medical institutions and training for medical professionals. We will establish a foundation for regulatory approval and distribution in each country, build medical professionals' understanding of the product and experience using it, and turn that into long-term growth."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing